ATAI Life Sciences NV (9VC) — Financial Flexibility Index
ATAI Life Sciences NV (9VC) has a Financial Flexibility Index of -0.22x as of September 2025. Free cash flow of €-17.90 Million (operating CF €-23.26 Million minus capex €5.36 Million) represents 0% of total liabilities (€79.91 Million). Also explore ATAI Life Sciences NV annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ATAI Life Sciences NV Financial Flexibility Index (2019–2024)
Historical Financial Flexibility Index trend for ATAI Life Sciences NV across 6 annual periods. Check ATAI Life Sciences NV (9VC) strategic investment index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for ATAI Life Sciences NV (2019–2024)
Year-by-year free cash flow to debt coverage for ATAI Life Sciences NV. For the full company profile including market capitalisation, see ATAI Life Sciences NV stock valuation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.92x | €-82.34 Million | €-82.44 Million | €42.83 Million | ▼ -13.1% |
| 2023 | -1.70x | €-83.53 Million | €-84.12 Million | €49.16 Million | ▲ +34.8% |
| 2022 | -2.61x | €-103.44 Million | €-104.47 Million | €39.67 Million | ▼ -18.4% |
| 2021 | -2.20x | €-62.12 Million | €-63.25 Million | €28.21 Million | ▼ -72.1% |
| 2020 | -1.28x | €-20.71 Million | €-20.77 Million | €16.18 Million | ▲ +59.5% |
| 2019 | -3.16x | €-7.83 Million | €-7.85 Million | €2.48 Million | — |